Stock Analysis
- Israel
- /
- Medical Equipment
- /
- TASE:SOFW
SofWave Medical First Quarter 2024 Earnings: US$0.029 loss per share (vs US$0.11 loss in 1Q 2023)
SofWave Medical (TLV:SOFW) First Quarter 2024 Results
Key Financial Results
- Revenue: US$13.2m (up 27% from 1Q 2023).
- Net loss: US$983.0k (loss narrowed by 74% from 1Q 2023).
- US$0.029 loss per share (improved from US$0.11 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
SofWave Medical shares are up 3.4% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with SofWave Medical, and understanding it should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether SofWave Medical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TASE:SOFW
SofWave Medical
Engages in the development, production, marketing, and distribution of an ultrasound technology for treating fine lines and wrinkles in Israel and internationally.